PortfoliosLab logo
Alkem Laboratories Limited (ALKEM.NS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

Highlights

Market Cap

₹604.40B

EPS (TTM)

₹180.04

PE Ratio

28.08

Total Revenue (TTM)

₹98.21B

Gross Profit (TTM)

₹56.53B

EBITDA (TTM)

₹24.69B

Year Range

₹4,368.53 - ₹6,389.41

Target Price

₹5,365.71

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of ₹10,000 in Alkem Laboratories Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


220.00%240.00%260.00%280.00%300.00%320.00%340.00%December2025FebruaryMarchAprilMay
295.69%
249.98%
ALKEM.NS (Alkem Laboratories Limited)
Benchmark (^GSPC)

Returns By Period

Alkem Laboratories Limited (ALKEM.NS) returned -9.96% year-to-date (YTD) and -0.79% over the past 12 months.


ALKEM.NS

YTD

-9.96%

1M

7.07%

6M

-13.34%

1Y

-0.79%

5Y*

15.49%

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.70%

1M

13.67%

6M

-5.18%

1Y

9.18%

5Y*

14.14%

10Y*

10.43%

*Annualized

Monthly Returns

The table below presents the monthly returns of ALKEM.NS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-9.42%-8.23%5.07%4.80%-1.62%-9.96%
2024-3.97%3.31%-3.61%-2.20%-0.47%3.76%6.37%16.32%-1.91%-4.52%-2.37%-0.15%9.11%
20230.22%5.92%6.96%3.35%-4.28%4.56%13.26%-8.22%-1.01%3.22%26.91%10.14%74.36%
2022-2.34%-6.58%10.46%-10.23%-3.12%-4.78%7.56%-7.65%10.17%-3.72%-0.98%-3.82%-16.27%
20212.76%-8.68%1.75%-0.39%8.34%7.03%7.95%12.47%2.63%-9.30%-0.48%0.85%25.11%
202019.06%10.42%-11.41%11.76%-12.95%4.66%12.41%2.38%2.03%-5.17%7.87%2.98%46.67%
2019-3.39%-6.99%-0.12%-1.34%4.42%-6.99%4.37%4.82%4.81%4.86%1.57%-0.75%4.25%
2018-0.14%1.54%-10.69%-0.60%-3.01%-1.34%12.05%0.13%-2.83%-7.21%0.30%1.91%-10.93%
20172.44%28.36%2.96%-10.59%-2.02%-3.93%-1.27%-1.23%2.24%1.80%6.05%10.81%35.89%
2016-8.51%-6.93%8.03%-12.20%6.08%9.58%13.17%-1.21%7.33%-1.77%4.54%-4.19%10.84%
20157.49%7.49%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ALKEM.NS is 57, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ALKEM.NS is 5757
Overall Rank
The Sharpe Ratio Rank of ALKEM.NS is 6161
Sharpe Ratio Rank
The Sortino Ratio Rank of ALKEM.NS is 5252
Sortino Ratio Rank
The Omega Ratio Rank of ALKEM.NS is 5050
Omega Ratio Rank
The Calmar Ratio Rank of ALKEM.NS is 6262
Calmar Ratio Rank
The Martin Ratio Rank of ALKEM.NS is 5757
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Alkem Laboratories Limited (ALKEM.NS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The current Alkem Laboratories Limited Sharpe ratio is 0.24. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Alkem Laboratories Limited with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2025FebruaryMarchAprilMay
-0.03
0.52
ALKEM.NS (Alkem Laboratories Limited)
Benchmark (^GSPC)

Dividends

Dividend History

Alkem Laboratories Limited provided a 0.83% dividend yield over the last twelve months, with an annual payout of ₹42.00 per share.


0.40%0.60%0.80%1.00%1.20%₹0.00₹10.00₹20.00₹30.00₹40.00201620172018201920202021202220232024
Dividends
Dividend Yield
PeriodTTM202420232022202120202019201820172016
Dividend₹42.00₹40.00₹25.00₹34.00₹30.00₹25.00₹16.00₹13.00₹9.00₹15.70

Dividend yield

0.83%0.71%0.48%1.13%0.83%0.85%0.79%0.67%0.41%0.96%

Monthly Dividends

The table displays the monthly dividend distributions for Alkem Laboratories Limited. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025₹0.00₹37.00₹0.00₹0.00₹0.00₹37.00
2024₹0.00₹35.00₹0.00₹0.00₹0.00₹0.00₹0.00₹5.00₹0.00₹0.00₹0.00₹0.00₹40.00
2023₹0.00₹15.00₹0.00₹0.00₹0.00₹0.00₹0.00₹10.00₹0.00₹0.00₹0.00₹0.00₹25.00
2022₹0.00₹30.00₹0.00₹0.00₹0.00₹0.00₹0.00₹4.00₹0.00₹0.00₹0.00₹0.00₹34.00
2021₹0.00₹25.00₹0.00₹0.00₹0.00₹0.00₹0.00₹5.00₹0.00₹0.00₹0.00₹0.00₹30.00
2020₹0.00₹22.00₹0.00₹0.00₹0.00₹0.00₹0.00₹3.00₹0.00₹0.00₹0.00₹0.00₹25.00
2019₹0.00₹8.00₹0.00₹0.00₹0.00₹0.00₹0.00₹8.00₹0.00₹0.00₹0.00₹0.00₹16.00
2018₹0.00₹6.00₹0.00₹0.00₹0.00₹0.00₹0.00₹7.00₹0.00₹0.00₹0.00₹0.00₹13.00
2017₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹9.00₹0.00₹0.00₹0.00₹0.00₹9.00
2016₹9.70₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹6.00₹0.00₹15.70

Dividend Yield & Payout


Dividend Yield

Alkem Laboratories Limited has a dividend yield of 0.83%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.

Payout Ratio

Alkem Laboratories Limited has a payout ratio of 26.81%, which is quite average when compared to the overall market. This suggests that Alkem Laboratories Limited strikes a balance between reinvesting profits for growth and paying dividends to shareholders.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-25.00%-20.00%-15.00%-10.00%-5.00%0.00%December2025FebruaryMarchAprilMay
-20.32%
-10.64%
ALKEM.NS (Alkem Laboratories Limited)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Alkem Laboratories Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Alkem Laboratories Limited was 27.75%, occurring on Feb 25, 2025. The portfolio has not yet recovered.

The current Alkem Laboratories Limited drawdown is 20.32%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-27.75%Sep 16, 2024115Feb 25, 2025
-27.4%Jan 11, 2018358Jun 28, 2019132Jan 13, 2020490
-26.86%Sep 27, 2021158May 17, 2022296Jul 25, 2023454
-23.77%Jan 6, 201686May 13, 201649Jul 22, 2016135
-22.86%Mar 28, 201795Aug 11, 201795Dec 29, 2017190

Volatility

Volatility Chart

The current Alkem Laboratories Limited volatility is 8.19%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%December2025FebruaryMarchAprilMay
8.19%
12.17%
ALKEM.NS (Alkem Laboratories Limited)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Alkem Laboratories Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Alkem Laboratories Limited, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 2.4% positive surprise.


10.0020.0030.0040.0050.0060.00AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
52.34
51.12
Actual
Estimate

Valuation

The Valuation section provides an overview of how Alkem Laboratories Limited is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for ALKEM.NS, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ALKEM.NS has a P/E ratio of 28.1. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for ALKEM.NS relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ALKEM.NS has a P/S ratio of 4.8. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ALKEM.NS in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ALKEM.NS has a P/B value of 5.3. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items